Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

OmniAb Earnings Call: Key Takeaways

OmniAb delivered a strong Q3 2026, raising full-year revenue and cash guidance driven by milestone achievements and a major Eli Lilly partnership.

Why this was an Alfa AlertManagement guides 100% Revenue growth for 2027 (explicit single-year guidance).
Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthQ3 revenue $4M vs $2.2M; YTD $31.8M vs $10.3M.
Mgmt ConfidenceHigh confidence; raised 2026 revenue and cash outlook for second time.
Demand Visibility111 active partners; 433 active programs; $3B total contracted potential milestones.
Margin TrendsExploration consumables/software expected to drive high-margin recurring revenue streams.
Op. LeverageLowered 2026 OpEx guidance to $83M-$87M due to found efficiencies.
Pricing PowerAverage royalty rate of 3.4% across 433 active programs.
Vol vs PriceGrowth driven by milestone volume and new high-value service contracts.
Segment GrowthExploration revenue $2M-$3M in 2026; service revenue up on ion-channels.
New ClientsEli Lilly, Yamaya Inc., and Monash University added as new partners.
Capex & DebtYear-end cash guidance $53M-$57M; business expected to be cash break-even.
RegulatoryBaticlimab received approval in China for generalized myasthenia gravis.
CommentaryEmphasized 'Biological Intelligence' and AI-powered discovery via OmniDeep and Exploration platforms.
New LaunchesLaunched OmniTides for peptide discovery and expanded commercial access to Exploration.

Growth

Q3 revenue grew to $4M from $2.2M; year-to-date revenue reached $31.8M.

Outlook

Raised 2026 revenue guidance to $35M-$39M; exploration revenue expected to double in 2027.

Risks

Management used vague language regarding specific royalty pricing for Baticlimab and exploration consumable pull-through rates.

Source

The company's earnings call, NASDAQ: OABI, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

OmniAb, Inc.: key numbers

Share price
$4.89Close, Nov 16
Market cap
$713M
Shares outstanding
145.86MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Commercial Physical & Biological ResearchSIC 8731

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from OmniAb, Inc.

All →
8:24 AM ET 10-Q
Financial Results ▶ Call

OmniAb Q3 2026 Results: Net Loss of $15.7M, Loss Narrows

OmniAb, Inc. reported total revenue of $31.8 million for the nine months ended September 30, 2026, a significant increase from $10.3 million in the prior year period, primarily driven by license and milestone revenue. Despite the revenue growth, the company recorded a net loss of $29.3 million for the first nine months of 2026, though this was an improvement over the $50.6 million net loss reported for the same period in 2025.

Key figure
Net loss $15.7M
7:43 AM ET 8-K
Financial Results

OmniAb Financial Results

OmniAb reported Q3 2026 financial results, featuring revenue of $4.0 million and a net loss of $15.7 million. The company raised its full-year 2026 revenue guidance to $37-$39 million, citing strong licensing execution and momentum from its xPloration and OmniTides technologies.

“Our strong third-quarter 2026 performance reflects our licensing execution and our focus on driving value for our stakeholders within an efficient business model built on highly differentiated technologies.”

Matt Foehr, Chief Executive Officer of OmniAb

“In addition, the expanded commercial launch of xPloration®, the introduction of OmniTides™, and continued progress across our portfolio of milestone- and royalty-bearing partnered programs reinforce our confidence in the durability of our revenue base and our long-term growth potential. Based on our performance to date and our expectation for the remainder of the year, we are again raising our revenue guidance and cash outlook.”

Matt Foehr, Chief Executive Officer of OmniAb

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.